Physician profile
Brandy Augustine
NPI 1457404170
$3,034.08
in general payments reported to CMS, 2019-2025
21 companies · $946 in 2025
The $946 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $90.95 · 2021: $103 · 2022: $414 · 2023: $620 · 2024: $367 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,022.59 | 2022-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $431.62 | 2019-2021 | |
| Oyster Point Pharma, INC. | $165.22 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $155.05 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $141.32 | 2024-2025 | Vevye |
| Astellas Pharma US INC | $128.90 | 2023 | |
| Coopervision INC. | $126.33 | 2022-2025 | Clariti Contact Lens, Biofinity Contact Lens |
| Dompe US, INC. | $121.83 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $114.79 | 2022-2025 | Xiidra, Miebo, Infuse |
| Novartis Pharmaceuticals Corporation | $114.02 | 2020-2022 | |
| Alcon Vision LLC | $97.43 | 2025 | Rocklatan, Tryptyr |
| Abbvie INC. | $85.79 | 2023-2025 | Alphagan P, Vuity, Lumigan |
| Glaukos Corporation | $75.84 | 2019 | |
| Allergan, INC. | $63.85 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $62.11 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $31.41 | 2019 | |
| Biotissue Holdings INC. | $28.65 | 2025 | |
| Horizon Therapeutics Plc | $28.15 | 2023 | Tepezza |
| Shire North American Group INC | $13.60 | 2019 | |
| Visioneering Technologies, INC. | $13.10 | 2022 | |
| Quidel Corporation | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Augustine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.